For example, since the oncogene ERBB2 (HER2) is amplified in subgroups of glioblastoma and, stomach, uterine, bladder, and lung cancers, responsiveness to HER2-targeted therapy may or may not be analogous to that of HER2-amplified breast cancer [9, 10]. The gene discussed is ERBB2; the disease is lung cancer.